A Phase 4 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed at 12 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 41st largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 8 in phase 4, and was the 14th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 14 is below the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 34th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2007, is one of 7 in phase 4, and was the 15th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of efficacy and safety on the use of rotigotine in patients suffering from Parkinson's Disease during and after surgery requiring general anaesthesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine
Drug: Rotigotine
2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch; Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h; One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery.
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist.
Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Patient did not show unexpected symptoms Item 2: Handling was simple Item 3: Handling wasn't time-consuming Item 4: Patch is a considerable option
Time frame: After subject wakes up from general anesthesia
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist.
Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Switch to patch was easily feasible Item 2: Re-switch was easily feasible Item 3: Patient did not show unexpected symptoms Item 4: Patch is a feasible option
Time frame: 2 weeks after surgery
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient.
Questionnaire including 3 items Range of sum score: 3 to 18 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Therapy with patch was easily feasible Item 2: Symptoms of Parkinson's Disease were well controlled Item 3: I felt safe with the Parkinson patch
Time frame: 2 weeks after surgery
Plasma Concentration of Rotigotine After Use.
Time frame: 24 hours
| Milestone | Rotigotine |
|---|---|
| Started | 14 |
| Completed | 11 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Delay in operation | 2 |
Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Patient did not show unexpected symptoms Item 2: Handling was simple Item 3: Handling wasn't time-consuming Item 4: Patch is a considerable option
| Score on scale | Rotigotine |
|---|---|
| Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist. | 5.0 ± 1.8 |
| ng/ml | Rotigotine 2 mg/24h | Rotigotine 6mg/24h | Rotigotine 8 mg/24h | Rotigotine 12 mg/24h | Rotigotine 14 mg/24h | Rotigotine 16 mg/24h |
|---|---|---|---|---|---|---|
| Plasma Concentration of Rotigotine After Use. | 0.1640 ± 0 | 0.2480 ± 0 | 0.7570 ± 0.1569 | 0.8405 ± 0.3302 | 0.8689 ± 0 | 1.6958 ± 2.1951 |
Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Switch to patch was easily feasible Item 2: Re-switch was easily feasible Item 3: Patient did not show unexpected symptoms Item 4: Patch is a feasible option
| Score on scale | Rotigotine |
|---|---|
| Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist. | 5.2 ± 2.2 |
Questionnaire including 3 items Range of sum score: 3 to 18 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Therapy with patch was easily feasible Item 2: Symptoms of Parkinson's Disease were well controlled Item 3: I felt safe with the Parkinson patch
| Score on scale | Rotigotine |
|---|---|
| Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient. | 3.9 ± 1.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 4/14 (28.6%) | 10/14 (71.4%) |
| Event | Rotigotine |
|---|---|
| Ventricular asystoleCardiac disorders | 1/14 |
| Joint dislocationInjury, poisoning and procedural complications | 1/14 |
| Post procedural haematomaInjury, poisoning and procedural complications | 1/14 |
| HallucinationPsychiatric disorders | 1/14 |
| Event | Rotigotine |
|---|---|
| Procedural painInjury, poisoning and procedural complications | 5/14 |
| ConstipationGastrointestinal disorders | 3/14 |
| NauseaGastrointestinal disorders | 3/14 |
| Urinary tract infectionInfections and infestations | 3/14 |
| Iron deficiencyMetabolism and nutrition disorders | 2/14 |
| Sleep disorderPsychiatric disorders | 2/14 |
| PruritusSkin and subcutaneous tissue disorders | 2/14 |
| AnaemiaBlood and lymphatic system disorders | 1/14 |
| Ear PainEar and labyrinth disorders | 1/14 |
| DiarrhoeaGastrointestinal disorders | 1/14 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 12 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 68.7 ± 5.9 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 7 |
| Male | 7 |
| Region of Enrollment(participants) | Rotigotine |
|---|---|
| Germany | 14 |
The record gives a start of Sep 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine